London’s Engitix Raises €21M To Advance ECM-Focused Cancer And Fibrosis Therapies

The financing was provided by Netherton Investments, a fund investing on behalf of Mike Platt, co-founder and Managing Director of BlueCrest Capital Management.

“Closing this financing strengthens our ability to translate Engitix’s unique ECM understanding into a growing pipeline of targeted therapeutics,” said Giuseppe Mazza, CEO and co-founder of Engitix. “Our platform and dataset position us to accelerate preclinical development across oncology and fibrosis programs and build differentiated ECM-targeted therapeutics with the potential to meaningfully improve patient outcomes.”

In 2025 European biotech continued to see strong funding across oncology, fibrosis and related therapeutic areas, with Engitix’s €21 million Series A extension fitting into a broader wave of mid- to late-stage investments.

Read Also - BrightHeart Raises €11M To expand FDA-Cleared Prenatal Ultrasound Platform In US And Europe

Comparable rounds include TargED Biopharmaceuticals (€21.5M, Netherlands), FoRx Therapeutics (€42M, Switzerland) Adcytherix (€105M, France) and Tubulis (€308M, Germany). The UK also saw activity with Trogenix (€80M) and Scripta Therapeutics (€10M+). Additional rounds include Italy’s NanoPhoria (€83.5M) and Ireland’s Aerska (€17M), collectively representing over €600M in disclosed biotech funding highlighting sustained investor interest.

Founded in 2016 Engitix develops therapies targeting the extracellular matrix (ECM) to treat cancer and fibrosis. By combining large scale ECM datasets with translational biology and drug development Engitix is building a pipeline of differentiated therapeutics that act within disease tissue microenvironments.

The company maintains a strategic drug discovery partnership with Dompé farmaceutici and development collaborations with Takeda for advanced fibrotic liver diseases.

Mike Platt, Investor Director, added: “Engitix has developed a compelling strategy at the intersection of data, biology, and drug development. I’m pleased to continue supporting Engitix as it advances its programmes in fibrosis and solid tumours.”

The new funding will be used to advance preclinical development across Engitix’s proprietary ECM-targeted pipeline for solid tumours and fibrosis, and to further expand and apply its platform, built on one of the largest proprietary ECM datasets in these disease areas.

About Engitix Therapeutics

Engitix Therapeutics is a UK biotech company reimagining drug discovery for fibrosis and cancer. Using its proprietary human extracellular matrix (ECM) platform, Engitix develops a pipeline of innovative therapies targeting fibrosis and solid tumours, aiming to improve outcomes for patients with life-threatening diseases.